Top ▲


Target id: 2766

Nomenclature: CD38

Family: CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     CD38 has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 300 4p15.32 CD38 CD38 molecule 6
Mouse - 304 5 B3 Cd38 CD38 antigen
Rat 1 303 14q21 Cd38 CD38 molecule
Previous and Unofficial Names
ADP-ribosyl cyclase 1
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of CD38 with a novel CD38-targeting antibody SAR650984 (=isatuximab).
Ligand:  isatuximab
Resolution:  1.53Å
Species:  Human
References:  3

Download all structure-activity data for this target as a CSV file

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
isatuximab Hs Binding 8.5 – 10.0 pKd 7
pKd 8.5 – 10.0 (Kd 3x10-9 – 1x10-10 M) [7]
daratumumab Hs Antagonist 8.2 pKd 2
pKd 8.2 (Kd 6.06x10-9 M) [2]


Show »

1. Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 32 (2): 252-262. [PMID:29257139]

2. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010) Antibodies Against Cd38 For Treatment Of Multiple Myeloma. Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.

3. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C et al.. (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin. Cancer Res., 20 (17): 4574-83. [PMID:24987056]

4. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol., 155 (2): 925-37. [PMID:7608568]

5. Hamblin TJ. (2003) CD38: what is it there for?. Blood, 102: 1939-1940.

6. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol., 144 (7): 2811-5. [PMID:2319135]

7. Park PU, Bartle L, Skaletskaya A, Golmakher V, Tavares D, Deckert J, Milol V, Blanc V. (2011) Novel anti-cd38 antibodies for the treatment of cancer. Patent number: US20110262454 A1. Assignee: Sanofi-Aventis. Priority date: 20/08/2015. Publication date: 27/10/2011.

8. Roepcke S, Plock N, Yuan J, Fedyk ER, Lahu G, Zhao L, Smithson G. (2018) Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect, 6 (3): e00402. [PMID:29864242]

How to cite this page

CD molecules: CD38. Last modified on 31/07/2018. Accessed on 16/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY,